Human PilotPubMed ID: 32488071·2020

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Schoof DD, Peoples GE, Beatty GR, et al.

Journal for ImmunoTherapy of Cancer, 2020 · n = 42

Key finding

Combination showed improved response rate (36% vs 24% checkpoint inhibitor alone); enhanced CD8+ TIL infiltration and activation.

Summary

Pilot study of thymosin alpha-1 combined with anti-PD-1 checkpoint inhibitor in advanced melanoma and lung cancer.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study

TNF-α and IL-2 modulation by thymosin alpha-1 in immune cells

Molecular Immunology · 2005 · In Vitro